Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

Benzinga Newsdesk www.benzinga.com Negative 81.2%

Neg 81.2% Neu 0% Pos 0%

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.